Today’s Boston Globe noted that the Boston regional office of the SEC is targeting unspecified Boston-area biotech companies for possible securities violations.
Given the propensity for certain biotech companies to engage in unscrupulous behavior, I doubt this office will encounter a shortage of workload.
Market Data 
Markets 
AI
